Added to YB: 2026-01-23
Pitch date: 2026-01-21
DRTS [bullish]
Alpha Tau Medical Ltd.
+7.74%
current return
Author Info
Anders Research shares equity research primarily focused on micro/small/mid-cap biotechnology. We follow companies with mechanistically differentiated approaches to large market opportunities, with special focus in neuroscience. Sign up for the newsletter.
Company Info
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer.
Market Cap
$606.2M
Pitch Price
$6.72
Price Target
13.00 (+80%)
Dividend
N/A
EV/EBITDA
-14.60
P/E
-13.62
EV/Sales
N/A
Sector
Health Care Equipment and Supplies
Category
growth
Alpha Tau (DRTS): Pancreatic, GBM, and Other Updates; Set Up For A Strong, Catalyst-Rich 2026
DRTS: Unique tumor-agnostic alpha radiation therapy w/ 5 active US indications. Key 2H26 catalysts: 30-pt pancreatic trial data, 10-pt GBM results, cSCC pivotal readout + potential approval 2027. FDA Breakthrough Device status, strong enrollment demand. $76M cash vs $5-6M/qtr burn. At $550M cap, targeting 50-100% upside by year-end on breakthrough data.
Read full article (8 min)